Isogelo

Magnesium chloride hexahydrate (together with potassium chloride, sodium chloride, calcium chloride dihydrate and sodium), the active ingredients in Isogelo, is an electrolyte solution presented as a sterile solution for injection for intravenous use. It helps correct electrolyte deficiencies and supports fluid balance in patients requiring replacement therapy.

GNH USA supplies Isogelo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Isogelo is an intravenous electrolyte solution used to restore and maintain normal electrolyte and fluid balance in several clinical situations.

- Electrolyte deficiency (hypomagnesemia, hypokalemia, hyponatremia, hypocalcemia): replenishes deficient ions and normalises serum concentrations. - Fluid replacement: provides isotonic fluid volume to address dehydration or blood loss. - Peri‑operative or critical‑care support: maintains electrolyte homeostasis during surgery, trauma or intensive care management.

Isogelo may be associated with a range of infusion‑related reactions.

Common Side Effects: - Injection site pain or erythema. - Mild hypermagnesemia presenting as flushing or warmth. - Transient hyperkalemia causing mild muscle weakness. - Slight increase in serum sodium leading to mild thirst.

Serious or Rare Side Effects: - Severe hypermagnesemia resulting in respiratory depression. - Life‑threatening hyperkalemia with cardiac arrhythmia. - Anaphylactic or severe hypersensitivity reaction. - Fluid overload causing pulmonary edema. - Cardiac arrhythmias due to rapid electrolyte shifts.

Before initiating Isogelo therapy, clinicians should evaluate the patient's electrolyte status and renal function.

- Assess baseline serum electrolytes: confirm deficiency before infusion. - Monitor cardiac rhythm: watch for arrhythmias during rapid correction. - Adjust infusion rate in renal impairment: slower rates reduce risk of accumulation. - Avoid in known hypermagnesemia, hyperkalemia, or severe hypernatremia. - Use caution in patients with heart failure or fluid overload risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Isogelo can interact with other agents that affect electrolyte balance or cardiac conduction.

Major Interactions (Avoid): - Concurrent administration of additional IV electrolyte solutions: risk of severe electrolyte overload. - Digoxin therapy combined with hyperkalemia from Isogelo: may precipitate digoxin toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may potentiate hyperkalemia; monitor potassium levels. - Loop diuretics: can cause rapid shifts in calcium and magnesium; adjust dosing. - Nephrotoxic antibiotics (e.g., aminoglycosides): monitor renal function and electrolyte trends.